Biotech Values

[DewDiligence]

GILD borrows a page from ABBV/ENTA in constructing a ‘Plan B’ for all-oral treatment of GT1 patients: adding a non-nuke as a third agent. Specifically, GILD just started a phase-2 trial with three choices for the addend to Sofosbuvir + Ledispavir: i) high-dose GS-9669; ii) low-dose GS-9669; and iii) ribavirin; all arms have a treatment duration of 8 weeks:

http://clinicaltrials.gov/ct2/show/NCT01984294

The trial includes 90 patients who are GT1a or Gt1b and are treatment-naïve or treatment-experienced. Results are expected in Mar 2014.